ArticleScientific reports2026
Functional ADAM12 variants modulate proteolytic activity and influence metabolic traits.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The high prevalence of insulin resistance and metabolic syndrome in Kuwait increases the risk of type 2 diabetes (T2D) and cardiovascular diseases development. Although the genetic contribution to insulin resistance and metabolic syndrome is established, the role of a disintegrin and metalloprotease 12 (ADAM12) in insulin resistance and T2D remains unclear. Our GWAS has identified four novel ADAM12 variants, namely, ADAM12-K170R rs112264074 [NP_003465.3:p.Lys170Arg], ADAM12-R176W rs140497576 [NP_003465.3:p.Arg176Trp], ADAM12-M662V rs115100580 [NP_003465.3:p.Met662Val], and ADAM12-I908V rs41303603 [NP_003465.3:p.Ile908Val]. These variants were associated with different metabolic traits, including FBG, HbA1c, low- (LDL) and high-density lipoprotein (HDL), total cholesterol (TC), and diastolic and systolic blood pressure. Using an independent replication cohort, the association of ADAM12-I908V with FBG was confirmed, and an association with HbA1c, LDL, and TC was found. In addition, ADAM12-K170R showed associations with waist-hip ratio in diabetic patients, and ADAM12-M662V associated with HDL, TC, and HbA1c in healthy controls, while ADAM12-R176W variant was not detected in the replication cohort. Moreover, we examined the impact of ADAM12 variants on its proteolytic activity and results show that 176W and 662V variants had higher activity in cell lysate supernatants, but only 662V and 908V variants had higher activity in intact cells, suggesting that enzyme activity dysregulation may contribute to the development of metabolic syndrome and T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.